Yes, mirtazapine causes drowsiness within the first day of treatment
Mirtazapine produces significant sedation that begins immediately after the first dose, making it particularly useful when rapid sleep improvement is needed. This is a well-established effect supported by both FDA labeling and clinical guidelines.
Immediate Onset of Sedation
The sedative effects of mirtazapine occur rapidly:
First-dose effect: Research demonstrates that alertness ratings drop significantly after the very first dose of mirtazapine, with patients reporting subnormal alertness levels immediately following initial administration 1. This sedation begins within hours of the first dose.
FDA-documented somnolence: The FDA label clearly identifies somnolence as one of the most common adverse effects, occurring in 54% of patients in clinical trials (compared to 18% with placebo) 2. This high frequency underscores the predictable nature of this effect.
Clinical guideline recognition: Multiple guidelines specifically recommend mirtazapine for its sedating properties. The 2016 NCCN Palliative Care guidelines list mirtazapine among "sedating antidepressants" for treating refractory insomnia, noting it should be given at bedtime 3. The 2002 Alzheimer's guidelines explicitly state mirtazapine "promotes sleep" 4.
Mechanism and Clinical Pattern
The drowsiness is pharmacologically predictable:
- Mirtazapine blocks histamine H1 receptors, which directly causes sedation
- The effect is dose-dependent at lower doses (paradoxically, higher doses may be less sedating due to increased noradrenergic activity)
- Standard starting dose is 7.5-15 mg at bedtime, specifically timed to leverage the sedative effect 4
Temporal Course
While the sedation begins immediately:
- Peak effect: Most pronounced in the first 1-2 weeks of treatment 5
- Tolerance development: The sedative effects typically become milder and more transient over time, decreasing despite dose increases 6
- Recovery pattern: One study showed alertness ratings recovered after the second dose and progressively improved to 18% above baseline by treatment end, though initial sedation was marked 1
Clinical Implications
The FDA medication guide explicitly warns patients: "Mirtazapine tablets can cause sleepiness or may affect your ability to make decisions, think clearly, or react quickly" 2. Patients must be counseled to:
- Avoid driving or operating machinery until they know how the medication affects them
- Take the medication at bedtime to minimize daytime impairment
- Expect drowsiness, particularly in the first days of treatment
Important Caveats
- Discontinuation risk: Somnolence is the leading cause of treatment discontinuation, occurring in 10.4% of patients (versus 2.2% with placebo) 2
- Overdose presentation: In overdose situations, the primary symptom is "excessive but transient somnolence" 2, 6
- Combination risks: The FDA warns about combining mirtazapine with benzodiazepines due to risk of oversedation and respiratory depression 7, 2
The drowsiness within the first day is not just possible—it's expected and clinically utilized. This makes mirtazapine particularly valuable when treating depression with prominent insomnia or anxiety, but requires appropriate patient counseling about immediate functional impairment.